The evolving UK environment surrounding entheogens is increasingly complex, demanding careful navigation. While clinical research into compounds like psilocybin and copyright continues to unfold, and patient access via private clinics is expanding, the legal framework remains ambiguous. This presents a unique situation for both patients interested